New hope for rare obesity: 2-Year drug trial launches

NCT ID NCT07156578

ENROLLING_BY_INVITATION Disease control Sponsor: Rhythm Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 25 times

Summary

This study tests the long-term safety and effects of a drug called bivamelagon in 25 people with hypothalamic obesity, a rare condition causing severe weight gain. Participants who completed a prior study will take the drug for up to 2 years. Researchers will monitor side effects and changes in weight and body mass index.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOTHALAMIC OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Birmingham Women's and Children's NHS Foundation Trust

Birmingham, B15 2TG, United Kingdom
Children's Hospital Colorado

Aurora, Colorado, 80045, United States
Columbia University

New York, New York, 10027, United States
Great Ormond Street Hospital for Children

London, WC1N 3JH, United Kingdom
St. Jude Children's Research Hospital

Memphis, Tennessee, 38105, United States
The University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27514, United States
Tufts Medical Center

Boston, Massachusetts, 02111, United States
University of Cambridge

Cambridge, CB2 1TN, United Kingdom
University of Iowa Children's Hospital

Iowa City, Iowa, 52242, United States

Conditions

Explore the condition pages connected to this study.

HYPOTHALAMIC OBESITY